TrialClinical and translational science2021

SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.

Naomi Fei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.